The Claim
High-dose eicosapentaenoic acid (EPA) is associated with a significant reduction in low-attenuation plaque volume in patients with acute coronary syndrome on statin therapy, while the absence of EPA use is associated with increased low-attenuation plaque volume over a 1–2 year period.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with heart problems who take a high dose of EPA, a type of fish oil, tend to have less of a dangerous type of plaque in their arteries over a year or two, while those who don’t take it tend to have more of this plaque.
See the scientific wording
High-dose eicosapentaenoic acid (EPA) is associated with a significant reduction in low-attenuation plaque volume — a marker of lipid-rich, unstable plaque — in patients with acute coronary syndrome on statin therapy, while no EPA use is linked to increased low-attenuation plaque volume over 1–2 years.
What the research says
1 studyPeople with heart problems who took a high dose of EPA (a type of fish oil) along with their statin medicine had less dangerous fatty plaque in their arteries over time, while those who didn’t take EPA had more. So EPA helped stabilize their heart plaques.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.